

**Discussions with leaders:** *JNM* editor-in-chief Johannes Czernin, with Caius Radu, continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Antoni Ribas, MD, PhD, about advancing cancer research and treatment. . . . . **Page 1178**

**Image-guided HIFU in nuclear medicine:** Zhang and colleagues present a state-of-the-art review of the principles and clinical applications of image-guided high-intensity focused ultrasound, including examples of future potential development. . . . . **Page 1181**

**Cardiac PET and the future:** Di Carli offers perspective on the changing epidemiology and pathobiology of coronary artery disease, the efficacy of conventional imaging tools, and the advantages of quantitative PET as a transformative modality in nuclear cardiology. . . . . **Page 1189**

**Pheochromocytoma and paraganglioma:** Carrasquillo and colleagues provide an educational overview of the clinical features of pheochromocytoma and paraganglioma, as well as therapeutic strategies with  $^{131}\text{I}$ -MIBG and  $^{90}\text{Y}$ - or  $^{177}\text{Lu}$ -DOTA-somatostatin analogs. . . . . **Page 1192**

**Current clinical pretargeting:** Jallinoja and Houghton survey the recent history of pretargeting radioimmunotherapy and therapy studies, challenges faced in human studies and regulatory approval, and future avenues for clinical translation. . . . . **Page 1200**

**Diversity in nuclear medicine:** Cheng and colleagues report on the results of a study designed to characterize the status in nuclear medicine of women and racial/ethnic groups underrepresented in medicine in the United States. . . . . **Page 1207**

**$^{18}\text{F}$ -FES PET for clinical dilemmas:** Boers and colleagues present findings from a retrospective study of the utility of  $^{18}\text{F}$ -FES PET imaging in resolving questions in breast cancer after standard workups. . . . . **Page 1214**

**Pretargeted immuno-PET in MTC:** Bodet-Milin and colleagues describe the results of analyses to determine the sensitivity of anti-carcinoembryonic antigen immuno-PET in relapsing medullary thyroid carcinoma

and compare these with conventional imaging and  $^{18}\text{F}$ -DOPA PET/CT. . . . . **Page 1221**

**$^{68}\text{Ga}$ -BMS-986192 for PD-L1 PET:** Robu and colleagues detail the development and pre-clinical evaluation of a  $^{68}\text{Ga}$ -labeled adnectin protein to facilitate imaging of PD-L1 expression in tumors. . . . . **Page 1228**

**PSMA PET for HCC:** Hirnas and colleagues assess the effects of  $^{68}\text{Ga}$ -prostate-specific membrane antigen-11 PET/CT neovasculature imaging on disease staging, prognostics, and management of patients with hepatocellular carcinoma. . . . . **Page 1235**

**Expanding PSMA theranostics:** Brenner and colleagues offer perspective on the potential for nonprostatic applications of prostate-specific membrane antigen-based theranostics, particularly in tumors with high need for therapy improvement. . . . . **Page 1242**

**MSG and  $^{68}\text{Ga}$ -PSMA PET/CT:** Armstrong and colleagues use  $^{68}\text{Ga}$ -PSMA-11 PET to determine the effect of monosodium glutamate administration on prostate-specific membrane antigen-radioligand biodistribution in healthy organs and tumor lesions in men with prostate cancer. . . . . **Page 1244**

**Diuresis and dual-time-point PSMA PET:** Alberts and colleagues investigate a modified prostate-specific membrane antigen PET/CT protocol combining late additional imaging with hydration and forced diuresis in assessment for uncertain findings. . . . . **Page 1252**

**$^{68}\text{Ga}$ -PSMA PET/CT versus nano-MRI:** Schilham and colleagues compare characteristics of prostate-specific membrane antigen PET/CT and ferumoxtran-10 nanoparticle-enhanced MRI to determine the feasibility of their complementary use for prostate cancer imaging. . . . . **Page 1258**

**SUV and TBR in  $^{18}\text{F}$ -DCFPyL PET/CT:** Bodar and colleagues explore whether SUV on PET/CT, as compared with tumor-to-blood ratio, can provide adequate quantification of uptake of this ligand in a patient cohort with low prostate cancer burden. . . . . **Page 1264**

**PSMA PET and bipolar androgen therapy:** Markowski and colleagues analyze the utility of  $^{18}\text{F}$ -DCFPyL PET/CT in determining

clinical response to this emerging treatment for metastatic castration-resistant prostate cancer. . . . . **Page 1270**

**PRRT plus  $^{131}\text{I}$ -MIBG:** Bushnell and colleagues report on preliminary results of a study on the addition of  $^{131}\text{I}$ -MIBG to  $^{90}\text{Y}$ -DOTA-TOC peptide-receptor radionuclide therapy for progressive metastatic neuroendocrine tumors. . . . . **Page 1274**

**NETPET score in lung NENs:** Chan and colleagues describe evaluation of this prognostic score, combining  $^{18}\text{F}$ -FDG and somatostatin receptor imaging agent uptake data, in bronchial neuroendocrine neoplasms. . . . . **Page 1278**

**$^{18}\text{F}$ -FCH PET metaanalysis:** Whitman and colleagues summarize data on the sensitivities and specificities of  $^{18}\text{F}$ -FCH PET in localizing hyperparathyroidism and compare these results with those from comparable  $^{99\text{m}}\text{Tc}$ -sestamibi scans. . . . . **Page 1285**

**Tau<sup>1Q</sup> algorithm:** Whittington and Gunn report on development of a PET data quantification algorithm for the complex spatial distribution of tau radiotracers, with specific promise in longitudinal analyses and early detection of tau deposition. . . . . **Page 1292**

**Hypermetabolism on brain  $^{18}\text{F}$ -FDG PET:** Chugani discusses and provides examples of the multiple causes of hypermetabolism on  $^{18}\text{F}$ -FDG PET studies that should not be interpreted as seizure activity. . . . . **Page 1301**

**DIR PET tracers:** Barret and colleagues characterize in nonhuman primates 2 novel  $\text{D}_1$  receptor agonist PET radiotracers, racemic  $^{18}\text{F}$ -MNI-800 and its more active atropisomeric (–)-enantiomer,  $^{18}\text{F}$ -MNI-968. . . . . **Page 1307**

**Enhancing robot-assisted radioguided surgery:** Azargoshasb and colleagues describe development of a real-time fluorescence-video-based tracking method that integrates the DROP-IN  $\gamma$ -probe with navigated robotic surgery. . . . . **Page 1314**

**Advanced imaging for primary lateral sclerosis:** Masrori and colleagues present results from work-up imaging with MRI,  $^{123}\text{I}$ -FP-CIT PET,  $^{18}\text{F}$ -PE2I PET, and  $^{18}\text{F}$ -FDG PET in a patient with unilateral mild paresis, slowing of the upper limb, and parkinsonism. . . . . **Page 1318**